Inhibition of pancreatic lipase by inhibitors such as orlistat is a principal therapeutic mechanism for suppressing the digestion of dietary triacylglycerols (lipolysis) and a strategy for treating obesity and hyperlipidemia [36]. This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.